ABSTRACT

Tirofiban can be used to treat patients with acute ischemic stroke (AIS), this study was to evaluate the efficacy and safety of tirofiban combined with heparin in the treatment of mild to moderate AIS. A total of 98 patients with mild to moderate AIS randomly were divided into 2 groups within 48 h: the treatment group treated with tirofiban and, and the control group treated with aspirin + clopidogrel. The treatment group was given the same scheme as the control group after the treatment of tirofiban combined with heparin for 48 h. It was found that, compared with the control group, a significant decreased National Institute of Health stroke scale (NIHSS) was found in 48 h and 14 d, especially to the Barthel index (BI) in the treatment group (P < 0.05). Furthermore, Modified Rankin Scale (MRS, ≤2) in the treatment group was significantly upregulated in 90 d (P < 0.05). However, there were no significant differences in the adverse drug reactions between the two groups. It was indicated that nerve function and long-term prognosis in patients undergoing heparin for mild to moderate AIS were obviously improved than the control group.

摘要

替罗非班可用于治疗急性缺血性卒中（AIS）患者，本研究旨在评价替罗非班联合肝素治疗轻中度AIS的疗效和安全性。共98例轻中度AIS患者在48 h内随机分为2组：治疗组给予替罗非班和治疗，对照组给予阿司匹林+氯吡格雷治疗。治疗组在替罗非班联合肝素治疗48 h后给予与对照组相同的方案。结果发现，与对照组相比，治疗组48 h和14 d的美国国立卫生研究院卒中量表（NIHSS）显着降低，尤其是Barthel指数（BI）（P < 0.05）。此外，修正 Rankin 量表 (MRS, ≤2）治疗组在90 d内显着上调（P < 0.05）。但两组药物不良反应无显着差异。表明轻中度AIS患者接受肝素治疗后神经功能及远期预后较对照组明显改善。